<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03946384</url>
  </required_header>
  <id_info>
    <org_study_id>BOVET 2019</org_study_id>
    <nct_id>NCT03946384</nct_id>
  </id_info>
  <brief_title>Mutation p.Ile112Thr : Discrepancy Between Factor IX Level and Bleeding Phenotype</brief_title>
  <acronym>HÃ©mophilie B</acronym>
  <official_title>Discrepancy Between Factor IX Level and Bleeding Phenotype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It appears that the mutation p.Ile112Thr in the factor IX gene confers a discrepancy between
      mild factor IX level and severe bleeding phenotype. Databases and litterature analysis are
      poor on this matter. The goal of this study is to compile bleeding phenotype in patients with
      this specific mutation to prove the clinico-biological discordance in order to improve
      patient care and follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2019</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding phenotype</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
    <description>bleeding phenotype in patients with p.Ile112Thr in factor IX gene</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <description>Hemophilia B with p.Ile112Thr mutation on factor IX gene</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collection</intervention_name>
    <description>data collection on the history of the disease, hemophilia</description>
    <arm_group_label>patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hemophilia B
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hemophilia B with p.Ile112Thr mutation on factor IX gene

        Exclusion Criteria: None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julien BOVET</last_name>
    <phone>3.80.29.33.14</phone>
    <phone_ext>+33</phone_ext>
    <email>julien.bovet@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Julien BOVET</last_name>
      <phone>3.80.29.33 14</phone>
      <phone_ext>+33</phone_ext>
      <email>julien.bovet@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Celine ROW</last_name>
      <phone>3.80.29.37.28</phone>
      <phone_ext>+33</phone_ext>
      <email>celine.row@chu-dijon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

